Kiniksa Pharmaceuticals Receives Consensus 'Buy' Rating from Analysts

Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) have recently been recommended as a "Buy" by five research firms monitoring the company, as noted by MarketBeat.com. All five analysts assigned a buy rating to the stock, with an average 12-month target price set at $36.60.

In recent reports, various analysts provided updates on Kiniksa Pharmaceuticals. Evercore ISI raised their price target for the company's shares from $30.00 to $35.00 and designated Kiniksa as "outperform." This adjustment was made in a report dated October 30th. Similarly, JPMorgan Chase & Co. increased their target price from $39.00 to $40.00, giving the stock an "overweight" rating in a note published on November 5th. Additionally, Jefferies Financial Group began coverage on Kiniksa Pharmaceuticals, assigning a "buy" rating and targeting a price of $40.00 for the shares.

Insider Transactions

In other news about Kiniksa Pharmaceuticals, COO Eben Tessari sold 17,500 shares on September 23rd at an average price of $24.99, totaling $437,325. Following this sale, Tessari now owns 116,975 shares, valued at approximately $2.92 million, marking a 13.01% reduction in ownership. The transaction details are accessible via a filing with the Securities & Exchange Commission.

Moreover, CFO Mark Ragosa sold 8,969 shares on December 3rd, receiving an average price of $21.45 for a total of $192,385.05. After this transaction, Ragosa holds around 22,958 shares worth roughly $492,449. The disclosure for this trade can be found in public records. Over the past three months, insiders have sold a total of 44,592 shares valued at over $1.11 million. Notably, company insiders own 54.57% of Kiniksa Pharmaceuticals stock.

Institutional Investor Activity

Various hedge funds and institutional investors have also modified their positions in Kiniksa Pharmaceuticals. Quarry LP recently acquired a new stake in the company during the third quarter, estimated at about $50,000. CWM LLC significantly increased its stake by 443.0%, now owning 2,449 shares valued at $61,000 after acquiring an additional 1,998 shares. nVerses Capital LLC established a new position worth $80,000 while Ashton Thomas Private Wealth LLC purchased shares valued at $100,000 in the second quarter. Furthermore, Lynx1 Capital Management LP also bought into Kiniksa Pharmaceuticals, investing $177,000 this past quarter. Institutional investors currently hold 53.95% of the company's shares.

Kiniksa Pharmaceuticals Stock Performance

Kiniksa Pharmaceuticals shares opened at $20.59 on Friday, reflecting a 1-year low of $16.56 and a 1-year high of $28.15. The company's market capitalization is approximately $1.49 billion, with a price-to-earnings (PE) ratio of -147.06 and a beta of 0.27. The stock's average moving prices over 50 days and 200 days stand at $22.79 and $23.09, respectively.

On October 29th, Kiniksa Pharmaceuticals disclosed its quarterly earnings report, revealing an earnings per share (EPS) of ($0.18), which fell short of the expected ($0.01) by $0.17. The firm reported a negative return on equity of 7.31% and a negative net margin of 2.36%. Revenue for the quarter reached $112.21 million, slightly exceeding analyst expectations of $111.51 million. This revenue marks a 67.4% increase compared to the previous year, where EPS was ($0.20). Analysts project that Kiniksa Pharmaceuticals will record an EPS of -0.55 for the ongoing fiscal year.

Overview of Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company dedicated to discovering, acquiring, developing, and commercializing therapeutic solutions for patients with serious conditions that have significant unmet medical needs worldwide. Their key product candidates include ARCALYST, targeting recurrent pericarditis, Mavrilimumab for giant cell arteritis, Vixarelimab for chronic inflammatory skin conditions, and KPL-404, which modulates key immune responses.

Kiniksa, Pharmaceuticals, Investment